Gadopiclenol, initially invented by Guerbet with subsequent contribution of Bracco IP, is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity.1 The efficacy and safety of Gadopiclenol have been evaluated in MRI of the Central Nervous System, head and neck, thorax, abdomen, pelvis, and musculoskeletal system (refer to the approved USPI for full information).2 Details on Phase III clinical trials are available on www.ClinicalTrials.gov.
New contrast agent is officially available for use in hospitals and clinics
Bracco’s new MRI contrast agent is now available for use in hospitals and clinics, according to the company’s latest announcement.
Bracco Imaging Announces Global Collaboration Agreement with Guerbet for Gadopiclenol
Bracco Imaging announced a global strategic collaboration agreement with Guerbet for Gadopiclenol
Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol
Companies will collaborate on manufacturing and research and development for future indications, and will commercialize Gadopiclenol independently under separate brands.
Bracco prepares launch of its version of gadopiclenol MRI contrast
September 21, 2022 -- Contrast agent developer Bracco is preparing for a commercial launch of its version of gadopiclenol, the new MRI gadolinium-based contrast agent (GBCA) that has received approval in the U.S. Bracco will sell the agent as Vueway.